Orion stock

ORNAV · Nasdaq Helsinki · EUR

€103.00Change from previous close: +0.19%Absolute change: +€0.20

Close · November 16, 2026

Price history

+71.95% over the period

1 year: from €59.90 (November 17, 2025) to €103.00 (November 16, 2026), +71.95%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 16, 2026€103.00
October 30, 2026€99.70
September 30, 2026€82.70
August 31, 2026€78.90
July 31, 2026€80.70
June 30, 2026€71.70
May 29, 2026€71.20
April 30, 2026€68.10
March 31, 2026€69.50
February 27, 2026€67.80
January 30, 2026€69.20
December 30, 2025€63.30
November 28, 2025€61.80
November 17, 2025€59.90

At a glance

  • The company

    Develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and self-care products across multiple markets

  • Latest results

    Quarter to June 30, 2026 · EPS €1.00 (estimate €0.96)

TickerLandia's take on Orion

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low€58.90
52-wk high€103.60

−0.58% from the 52-week high

TickerLandia Fingerprint: Orion

Compared with similar companies: very strong momentum, very high financial strength, and very high growth.

Financials and price compared with 25 companies in the drug manufacturers - general industry, worldwide. Momentum and risk compared with 1,160 European stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Orion is pricier than in the past and in line with similar companies

On the latest fiscal year's earnings (2025), Orion's P/E today is 28.9, above the median of its last 9 fiscal years (23.9; between 17.8 and 28.7 from 2016 to 2025). Orion's P/E (trailing 12 months): 22.0, in line with the median of a group of 10 similar companies (21.5).

P/E compared with its history

Compared with 10 similar companies

Orion's metrics compared with similar companies
MetricOrionPosition in the groupBand
P/E (trailing 12 months)22.0Middle
Operating margin38.1%High
ROE54.5%High
Debt/equity0.09Low
Price/book10.3High

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Orion. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

€521.6M

Latest quarter · Q2 2026

Net income

€140.2M

Latest quarter · Q2 2026

Quarterly net margin

26.9%

Latest quarter · Q2 2026

Numbers and valuation

Full valuation
Market cap
€14.42B
P/E
22.0
EPS
€4.68
Volume
3.64K
Daily trading
€1.11M
Dividend yield
1.75%
Last ex-dividend on October 19, 2026

How Orion is changing

All results
  • Revenue grew 12.1% a year on average over the last 3 years

  • Less cash than profit: free cash flow equal to 41% of net income

Returns

Orion returns with dividends

€1,000 invested in Orion 5 years ago, on November 16, 2021, would be worth €3,234 today with dividends reinvested: +223.39% in total, +26.46% per year. On price alone it would be €2,739 (+173.94%).

PeriodOrion€1,000 becomes
1 month+18.39%€1,184
6 months+52.14%€1,521
Year to date+62.72%€1,627
1 year+76.06%€1,761
3 years+206.27%€3,063
5 years+223.39%€3,234
10 years+279.71%€3,797

From 1 year up with dividends reinvested, before taxes; under a year price only. Calculate your investment

The chart in detail

Orion: technical analysis

Orion is in an uptrend: the price is above its 50- and 200-session moving averages, and the 200-session average is rising. The price is at its all-time closing high.

Trend
Upward
RSI (14 sessions)
84
Above 70: a strong rise in a short time
vs 200-session average
+35.38%

Active signals

  • RSI above 70: the stock has risen a lot in a short time.

    since October 21, 2026

Support and resistance

Price areas where Orion has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. No resistance above: the price is near the highs of the year
  2. Last price€103.00
  3. Support€81.15−21.21%2 touches, last on September 3, 2026
  4. Support€75.03−27.15%3 touches, last on October 5, 2026
  5. Support€71.43−30.65%7 touches, last on May 26, 2026

Volatility and risk

Volatility (60 sessions, annualised)
21.6%
Largest fall in the last year
−11.63%

In session, November 16, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Orion: seasonality

Average monthly price change over 22 years

+3.4%Jan+0.7%Feb−2.0%Mar+1.5%Apr+1.7%May+1.6%Jun+1.7%Jul+0.2%Aug+1.1%Sep+1.3%Oct−0.0%Nov+2.1%Dec

Over the last 22 years, the strongest month for Orion has been January: +3.39% on average, positive in 15 years out of 22. The weakest has been March: −2.01% on average, positive in 10 years out of 22. November, the current month, has been positive in 12 years out of 22 (−0.03% on average).

Show chart data
MonthAverageMedianPositive years
January+3.39%+2.25%15 of 22
February+0.71%+0.36%12 of 22
March−2.01%−1.34%10 of 22
April+1.48%+0.83%14 of 22
May+1.70%+4.53%13 of 22
June+1.62%+0.65%13 of 22
July+1.70%+3.10%13 of 22
August+0.20%−2.55%9 of 22
September+1.14%+2.29%13 of 22
October+1.28%+0.39%11 of 22
November−0.03%+1.57%12 of 22
December+2.09%+2.11%17 of 22

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Orion and its competitors

Nubeqa, Stalevo, Burana and the Easyhaler inhalers are among the products most associated with Orion Oyj, a Finnish pharmaceutical group that makes medicines for people and animals, as well as active pharmaceutical ingredients sold to other drug makers. Its prescription range covers Parkinson's disease, prostate cancer, asthma and COPD, heart failure, breast cancer and menopausal symptoms, while its veterinary products include Domitor and Sileo.

Headquarters
Espo, Finland
Employees
4,215
Orion and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
OrionORNAV$15.93B38.1%22.0+52.14%
RecordatiREC$12.11B32.6%21.0+2.62%
GrifolsGRF$8.76B18.9%16.4+28.19%
BayerBAYN$61.37B16.5%—+51.26%
VirbacVIRP$3.28B15.8%19.1+2.00%
GSKGSK$101.36B30.5%17.9+3.57%

Same industry or related industries, similar size. Compare Orion with its competitors · Full profile